SGLT2抑制剂在2型糖尿病中的心血管结局试验系统综述与荟萃分析:风险与获益的平衡
该系统综述与荟萃分析纳入5项双盲安慰剂对照国际心血管结局试验共46969例2型糖尿病患者,加权平均随访3.5年。SGLT2抑制剂降低全因死亡、主要不良心血管事件、心力衰竭住院和终末期肾病风险,但增加糖尿病酮症酸中毒和生殖器感染风险,截肢风险无显著差异。
要点
- SGLT2抑制剂降低全因死亡(IRR 0.86)、MACE(IRR 0.91)、HHF(IRR 0.69)和ESRD(IRR 0.67)。
- SGLT2抑制剂增加DKA(IRR 2.59)和生殖器感染(IRR 3.50)风险,截肢风险无显著差异(IRR 1.23)。
- 每1000例治疗3.5年,预计减少9例MACE、11例HHF、2例ESRD,同时诱发2例DKA和36例生殖器感染。
核心结论
- 在心血管疾病高风险2型糖尿病患者中,SGLT2抑制剂的心血管和肾脏获益仍然显著,尽管存在DKA风险甚至假设的截肢风险。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE截至2021年9月14日,纳入5项双盲、安慰剂对照国际随机心血管结局试验,共46969例2型糖尿病患者,加权平均随访3.5年,合并前心血管疾病患病率范围为40.6%至99.2%。
主要发现
- SGLT2抑制剂降低全因死亡风险(IRR 0.86 [95% CI 0.78, 0.95])。
- SGLT2抑制剂降低MACE风险(IRR 0.91 [95% CI 0.86, 0.96])。
- SGLT2抑制剂降低HHF风险(IRR 0.69 [95% CI 0.62, 0.76])。
- SGLT2抑制剂降低ESRD风险(IRR 0.67 [95% CI 0.53, 0.84])。
- SGLT2抑制剂增加DKA风险(IRR 2.59 [95% CI 1.57, 4.27])和生殖器感染风险(IRR 3.50 [95% CI 3.09, 3.95]),截肢风险无显著差异(IRR 1.23 [95% CI 1.00, 1.51])。
关键数值与推荐
- 每1000例接受SGLT2抑制剂治疗3.5年,预计平均减少死亡从70例降至61例,预防9例MACE、11例HHF和2例ESRD,同时诱发2例DKA和36例生殖器感染。
- 预计778例个体可避免以下所有结局:MACE、HHF、ESRD、截肢、DKA和生殖器感染。
- 生殖器感染的定义范围从「生殖器真菌感染」到「导致试验方案中止或被视为严重不良事件的生殖器感染」。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究仅限于聚合数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Cardiovascular outcome trials (CVOTs) have demonstrated the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i). However, serious adverse drug reactions have been reported. The risk/benefit ratio of SGLT2i remains unquantified. We aimed to provide an estimation of their risk/benefit ratio in individuals with type 2 diabetes. METHODS: We conducted a systematic review (MEDLINE, up to 14 September 2021) and meta-analysis. We included randomised CVOTs assessing SGLT2i in individuals with type 2 diabetes with or without other diseases. We used the Cochrane 'Risk of bias' assessment tool. The primary outcomes were overall mortality, major adverse cardiovascular events (MACE), hospitalisation for heart failure (HHF), end-stage renal disease (ESRD), amputation, diabetic ketoacidosis (DKA) and reported genital infections. For each outcome, we estimated the incidence rate ratio (IRR) with a 95% CI; we then computed the number of events expected spontaneously and with SGLT2i. RESULTS: A total of 46,969 participants from five double-blind, placebo-controlled international trials (weighted mean follow-up 3.5 years) were included. The prevalence of previous CVD ranged from 40.6% to 99.2%. The definition of reported genital infections ranged from 'genital mycotic infection' to 'genital infections that led to discontinuation of the trial regimen or were considered to be serious adverse events'. The number of included studies for each outcomes was five. The use of SGLT2i decreased the risk of all-cause death (IRR 0.86 [95% CI 0.78, 0.95]), MACE (IRR 0.91 [95% CI 0.86, 0.96]), HHF (IRR 0.69 [95% CI 0.62, 0.76]) and ESRD (IRR 0.67 [95% CI 0.53, 0.84]), and increased the risk of DKA (IRR 2.59 [95% CI 1.57, 4.27]) and genital infection (IRR 3.50 [95% CI 3.09, 3.95]) but not of amputation (IRR 1.23 [95% CI 1.00, 1.51]). For 1000 individuals treated over 3.5 years, SGLT2i are expected, on average, to decrease the number of deaths from 70 to 61, to prevent nine MACE, 11 HHF and two cases of ESRD, while inducing two DKA occurrences and 36 genital infections; 778 individuals are expected to avoid all the following outcomes: MACE, HHF, ESRD, amputation, DKA and genital infection. CONCLUSIONS/INTERPRETATION: Our study is limited to aggregate data. In a population of individuals with type 2 diabetes and a high CVD risk, the cardiovascular and renal benefits of SGLT2i remain substantial despite the risk of DKA and even the hypothetical risk of amputation. TRIAL REGISTRATION: OSF Registries: https://doi.org/10.17605/OSF.IO/J3R7Y FUNDING: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
引用
- Marilly E, Cottin J, Cabrera N, et al. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia. 2022. PMID: 35925319. doi:10.1007/s00125-022-05773-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。